Searched for: author%3A%22de+Kruijff%2C+R.M.%22
(1 - 14 of 14)
document
McLain, Derek R. (author), Brossard, Thomas W. (author), de Kruijff, R.M. (author), Kankanamalage, Pavithra H.A. (author), Rotsch, David A. (author)
Scandium-47 (<sup>47</sup>Sc) can be used in nuclear medicine as a therapeutic-diagnostic, or “theragnostic,” radioactive medical isotope for cancer detection and treatment. The <sup>47</sup>Sc isotope can be produced through the photonuclear reaction <sup>48</sup>Ti(γ,p)<sup>47</sup>Sc by irradiating enriched <sup>48</sup>Ti target material....
journal article 2023
document
Trapp, S. (author), Lammers, Tom (author), Engudar, Gokce (author), Hoehr, Cornelia (author), Denkova, A.G. (author), Paulssen, E. (author), de Kruijff, R.M. (author)
Background: The radionuclide Ga-68 is commonly used in nuclear medicine, specifically in positron emission tomography (PET). Recently, the interest in producing Ga-68 by cyclotron irradiation of [<sup>68</sup>Zn]Zn nitrate liquid targets is increasing. However, current purification methods of Ga-68 from the target solution consist of multi...
journal article 2023
document
van Dijk, Madeleine C. (author), de Kruijff, R.M. (author), Hagedoorn, P.L. (author)
Iron deficiency anemia can be treated with oral or intravenous Fe supplementation. Such supplementation has considerable effects on the human microbiome, and on opportunistic pathogenic micro-organisms. Molecular understanding of the control and regulation of Fe availability at the host-microbe interface is crucial to interpreting the side...
review 2022
document
Piergentili, I. (author), Bouwmans, Pepijn R. (author), Reinalda, L. (author), Lewis, R.W. (author), Klemm, Benjamin (author), Liu, H. (author), de Kruijff, R.M. (author), Denkova, A.G. (author), Eelkema, R. (author)
In certain tumor and diseased tissues, reactive oxygen species (ROS), such as H<sub>2</sub>O<sub>2</sub>, are produced in higher concentrations than in healthy cells. Drug delivery and release systems that respond selectively to the presence of ROS, while maintaining their stability in “healthy” biological conditions, have great potential as...
journal article 2022
document
Liu, H. (author), de Kruijff, R.M. (author), Laan, A.C. (author), Beekman, F.J. (author), van den Heuvel, E.J. (author), Ramakers, R.M. (author), Eelkema, R. (author), Denkova, A.G. (author)
A variety of polymer micelles are designed for the delivery of chemotherapeutic drugs to tumors. Although the promise of these nanocarriers is very high, in the clinic the effectivity is rather limited. Determining the in vivo fate of the micelles can greatly help to improve this treatment. Here, a simple and fast chelator-free method for...
journal article 2022
document
Roobol, Stefan J. (author), Hartjes, Thomas A. (author), Slotman, Johan A. (author), de Kruijff, R.M. (author), Kanaar, R. (author), Houtsmuller, A.B. (author), Denkova, A.G. (author), van Royen, M.E. (author), Essers, J. (author)
Polymersomes have the potential to be applied in targeted alpha radionuclide therapy, while in addition preventing release of recoiling daughter isotopes. In this study, we investigated the cellular uptake, post uptake processing and intracellular localization of polymersomes. Methods: High-content microscopy was used to validate polymersome...
journal article 2020
document
de Kruijff, R.M. (author)
A recent addition to the treatment options in external beam therapy, so-called FLASH radiotherapy, shows remarkable healthy-tissue-sparing properties in a number of pre-clinical studies without impacting the overall treatment efficacy. Its potential in clinical applications is attracting a great deal of interest in the medical community. The...
review 2019
document
Bikhezar, Fatima (author), de Kruijff, R.M. (author), van der Meer, A.J.G.M. (author), Torrelo Villa, G. (author), van der Pol, Susanne M.A. (author), Becerril Aragon, Gabriel (author), Gasol Garcia, Ana (author), Denkova, A.G. (author), Narayan, Ravi S. (author)
Background and purpose: Glioblastoma multiforme (GBM) is the most aggressive subtype of malignant gliomas, with an average survival rate of 15 months after diagnosis. More than 90% of all GBMs have activating mutations in the MAPK/ERK pathway. Recently, we showed the allosteric MEK1/2 inhibitor binimetinib (MEK162) to inhibit cell...
journal article 2019
document
de Kruijff, R.M. (author), Raavé, René (author), Kip, Annemarie (author), Molkenboer-Kuenen, Janneke (author), Roobol, Stefan J. (author), Essers, Jeroen (author), Heskamp, Sandra (author), Denkova, A.G. (author)
The use of nanoparticles as tumor-targeting agents is steadily increasing, and the influence of nanoparticle characteristics such as size and stealthiness have been established for a large number of nanocarrier systems. However, not much is known about the impact of tumor presence on nanocarrier circulation times. This paper reports on the...
journal article 2019
document
de Kruijff, R.M. (author), Raavé, R. (author), Kip, A. (author), Molkenboer-Kuenen, J. (author), Morgenstern, A. (author), Bruchertseifer, F. (author), Heskamp, S. (author), Denkova, A.G. (author)
Increasing attention is given to personalized tumour therapy, where α-emitters can potentially play an important role. Alpha particles are ideal for localized cell killing because of their high linear energy transfer and short ranges. However, upon the emission of an α particle the daughter nuclide experiences a recoil energy large enough to...
journal article 2019
document
de Kruijff, R.M. (author)
In radionuclide therapy, radioisotopes are used to irradiate tumours from within the body. Usually beta-emitters coupled to tumour-targeting molecules are used, which specifically accumulate at the tumour site. Instead of using beta-emitters, it is also possible to use radionuclides which emit an alpha particle upon decay. Alpha particles have a...
doctoral thesis 2018
document
de Kruijff, R.M. (author), van der Meer, A.J.G.M. (author), Windmeijer, C.A.A. (author), Kouwenberg, J.J.M. (author), Morgenstern, A. (author), Bruchertseifer, F. (author), Sminia, P. (author), Denkova, A.G. (author)
Alpha emitters have great potential in targeted tumour therapy, especially in destroying micrometastases, due to their high linear energy transfer (LET). To prevent toxicity caused by recoiled daughter atoms in healthy tissue, alpha emitters like <sup>225</sup>Ac can be encapsulated in polymeric nanocarriers (polymersomes), which are capable...
journal article 2018
document
Denkova, A.G. (author), de Kruijff, R.M. (author), Serra Crespo, P. (author)
Photothermal therapy (PTT) and photodynamic therapy (PDT) both utilize light to induce a therapeutic effect. These therapies are rapidly gaining importance due to the noninvasiveness of light and the limited adverse effect associated with these treatments. However, most preclinical studies show that complete elimination of tumors is rarely...
journal article 2017
document
De Kruijff, R.M. (author), Wolterbeek, H.T. (author), Denkova, A.G. (author)
This review presents an overview of the successes and challenges currently faced in alpha radionuclide therapy. Alpha particles have an advantage in killing tumour cells as compared to beta or gamma radiation due to their short penetration depth and high linear energy transfer (LET). Touching briefly on the clinical successes of radionuclides...
journal article 2015
Searched for: author%3A%22de+Kruijff%2C+R.M.%22
(1 - 14 of 14)